Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Omega Diagnostics ( (GB:CNSL) ) has shared an update.
Cambridge Nutritional Sciences plc announced that its subsidiary, Omega Diagnostics Limited, has settled its dispute with the Secretary of State for Health and Social Care on a ‘drop hands’ basis, meaning neither party admits liability, and each bears its own legal costs. As a result of the settlement, £2.5m of ‘Deferred Income’ will be reclassified as ‘Other exceptional Income’ for the year ending March 31, 2025, without impacting the company’s key performance indicator of adjusted EBITDA, highlighting that the settlement’s financial adjustments are not indicative of the underlying business performance.
More about Omega Diagnostics
Cambridge Nutritional Sciences plc (AIM: CNSL) is a specialist medical diagnostics company that focuses on promoting a personalized and functional approach to health and nutrition.
YTD Price Performance: 7.27%
Average Trading Volume: 399,350
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £7.02M
For a thorough assessment of CNSL stock, go to TipRanks’ Stock Analysis page.